YU41299A - Atropizomeri 3-aril-4(3h)-hinazolinona i njihova upotreba kao ampa-receptor antagonista - Google Patents

Atropizomeri 3-aril-4(3h)-hinazolinona i njihova upotreba kao ampa-receptor antagonista

Info

Publication number
YU41299A
YU41299A YU41299A YU41299A YU41299A YU 41299 A YU41299 A YU 41299A YU 41299 A YU41299 A YU 41299A YU 41299 A YU41299 A YU 41299A YU 41299 A YU41299 A YU 41299A
Authority
YU
Yugoslavia
Prior art keywords
atropisomers
ampa
aryl
quinazolinones
receptor antagonist
Prior art date
Application number
YU41299A
Other languages
English (en)
Inventor
Welch Willard Mckowan
Keith Michael Devries
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU41299A publication Critical patent/YU41299A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Antropizomeri formule (Ia), u kojima R2 je proizvoljno supstituisan aril ili heteroaril, R5 je alkil, halogen, CF3, alkoksi ili alkiltio, R5, R7 i R8 su vodonik ili halogen, i R3 je vodonik, halogen, CN, N(IV)-O, CF3, alkil ili alkoksi, korisni su kao AMPA receptor antagonisti, naročito u tretmanu neurodegenerativnih i CNS-povredom povezanih stanja.[Atropisomers of formula (Ia), wherein R2 is an optionally substituted aryl or heteroaryl, R5 is alkyl, halo, CF3, alkoxy or alkylthio, R6, R7 and R8 are hydrogen or halo, and R3 is hydrogen, halo, CN, NO2, CF3, alkyl or alkoxy, are useful as AMPA receptor antagonists, particularly in the treatment of neurodegenerative and CNS-trauma related conditions.
YU41299A 1997-02-28 1998-02-06 Atropizomeri 3-aril-4(3h)-hinazolinona i njihova upotreba kao ampa-receptor antagonista YU41299A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3890597P 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
YU41299A true YU41299A (sh) 2002-09-19

Family

ID=21902563

Family Applications (1)

Application Number Title Priority Date Filing Date
YU41299A YU41299A (sh) 1997-02-28 1998-02-06 Atropizomeri 3-aril-4(3h)-hinazolinona i njihova upotreba kao ampa-receptor antagonista

Country Status (40)

Country Link
US (1) US6306864B1 (sh)
EP (1) EP0968194B1 (sh)
JP (1) JP2000509731A (sh)
KR (1) KR100358636B1 (sh)
CN (1) CN1248248A (sh)
AP (1) AP859A (sh)
AR (1) AR011170A1 (sh)
AT (1) ATE267817T1 (sh)
AU (1) AU744028B2 (sh)
BG (1) BG103689A (sh)
BR (1) BR9807872A (sh)
CA (1) CA2282277C (sh)
DE (1) DE69824157T2 (sh)
DK (1) DK0968194T3 (sh)
DZ (1) DZ2440A1 (sh)
EA (1) EA001963B1 (sh)
ES (1) ES2219866T3 (sh)
GT (1) GT199800038A (sh)
HR (1) HRP980106A2 (sh)
HU (1) HUP0000914A3 (sh)
ID (1) ID22711A (sh)
IL (1) IL130900A0 (sh)
IS (1) IS1952B (sh)
MA (1) MA24484A1 (sh)
NO (1) NO313630B1 (sh)
NZ (1) NZ336628A (sh)
OA (1) OA11089A (sh)
PA (1) PA8447001A1 (sh)
PE (1) PE58399A1 (sh)
PL (1) PL335418A1 (sh)
PT (1) PT968194E (sh)
SK (1) SK113299A3 (sh)
TN (1) TNSN98035A1 (sh)
TR (1) TR199902093T2 (sh)
TW (1) TW504508B (sh)
UA (1) UA61097C2 (sh)
UY (1) UY24897A1 (sh)
WO (1) WO1998038173A1 (sh)
YU (1) YU41299A (sh)
ZA (1) ZA981666B (sh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL330042A1 (en) 1996-05-15 1999-04-26 Pfizer Novel 2,3-disubstituted 4(3h)-quinazolynones
US6323208B1 (en) * 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―4―オン誘導体の製造方法
WO2001081346A2 (en) * 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ATE420862T1 (de) 2000-06-12 2009-01-15 Eisai R&D Man Co Ltd 1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung
IL154350A0 (en) 2000-08-18 2003-09-17 Ajinomoto Kk New phenylalanine derivatives
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US6939968B2 (en) * 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
US20080146562A1 (en) * 2003-08-08 2008-06-19 Ulysses Pharmaceutical Products Inc., Halogenated quinazolinyl nitrofurans as antibacterial agents
CN1832941A (zh) * 2003-08-08 2006-09-13 尤利塞斯药品公司 作为抗菌剂的卤代喹唑啉基硝基呋喃类化合物
GB0325390D0 (en) * 2003-10-30 2003-12-03 Novartis Ag Organic compounds
EP1700850B1 (en) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalanine derivative
CN101031569B (zh) 2004-05-13 2011-06-22 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
TWI409070B (zh) 2005-11-04 2013-09-21 Hydra Biosciences Inc 用於調節trpv3功能之化合物
AU2007303846B2 (en) 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
ES2674719T3 (es) 2008-11-13 2018-07-03 Gilead Calistoga Llc Terapias para neoplasias hematológicas
US8440677B2 (en) 2009-03-24 2013-05-14 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
UY34656A (es) 2012-03-05 2013-10-31 Gilead Calistoga Llc Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación
CN103275086B (zh) * 2013-05-30 2015-04-15 温州大学 一种6-取代喹唑啉并喹唑啉酮化合物及其合成方法和用途
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
EA201690990A1 (ru) 2013-12-20 2016-11-30 Джилид Калистога Ллс Способы получения ингибиторов фосфатидилинозитол-3-киназы
US9533909B2 (en) 2014-03-31 2017-01-03 Corning Incorporated Methods and apparatus for material processing using atmospheric thermal plasma reactor
BR112016028642A2 (pt) 2014-06-13 2017-08-22 Gilead Sciences Inc composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
DE102014217021A1 (de) * 2014-08-27 2016-03-03 Skf Lubrication Systems Germany Ag Gehäuse für eine Vorrichtung zum dosierten Verteilen eines Mediums sowie eine Dosiereinrichtung zur Verwendung in dem Gehäuse
BR112021010953A2 (pt) 2018-12-14 2021-08-24 Eisai R&D Management Co., Ltd. Formulações farmacêuticas de base aquosa de compostos de 1,2-di-hidropiridina
EP4096661A4 (en) 2020-01-29 2024-03-06 Kamari Pharma Ltd COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISEASES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
US3748325A (en) * 1970-04-06 1973-07-24 Karamchand Premchand Private Process for the preparation of quinazolinone derivatives
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5777271A (en) * 1996-01-18 1998-07-07 Commscope, Inc. Cable having an at least partially oxidized armor layer
PL330042A1 (en) * 1996-05-15 1999-04-26 Pfizer Novel 2,3-disubstituted 4(3h)-quinazolynones

Also Published As

Publication number Publication date
NZ336628A (en) 2001-03-30
AP9801199A0 (en) 1998-03-31
HUP0000914A2 (hu) 2001-04-28
ATE267817T1 (de) 2004-06-15
AU744028B2 (en) 2002-02-14
NO994177L (no) 1999-08-27
ES2219866T3 (es) 2004-12-01
IL130900A0 (en) 2001-01-28
IS5140A (is) 1999-07-30
BG103689A (bg) 2000-11-30
PL335418A1 (en) 2000-04-25
HUP0000914A3 (en) 2001-09-28
UA61097C2 (uk) 2003-11-17
DE69824157D1 (de) 2004-07-01
CA2282277C (en) 2005-10-11
DE69824157T2 (de) 2004-10-14
KR20000075814A (ko) 2000-12-26
NO994177D0 (no) 1999-08-27
GT199800038A (es) 1999-08-13
OA11089A (en) 2003-09-22
EA199900693A1 (ru) 2000-02-28
EP0968194A1 (en) 2000-01-05
SK113299A3 (en) 2001-05-10
ZA981666B (en) 1999-08-27
JP2000509731A (ja) 2000-08-02
AU5676898A (en) 1998-09-18
AP859A (en) 2000-07-21
NO313630B1 (no) 2002-11-04
TNSN98035A1 (fr) 2005-03-15
TW504508B (en) 2002-10-01
EA001963B1 (ru) 2001-10-22
HRP980106A2 (en) 1999-02-28
US6306864B1 (en) 2001-10-23
IS1952B (is) 2004-10-13
CN1248248A (zh) 2000-03-22
CA2282277A1 (en) 1998-09-03
TR199902093T2 (xx) 1999-12-21
UY24897A1 (es) 2000-12-29
DK0968194T3 (da) 2004-08-16
AR011170A1 (es) 2000-08-02
PA8447001A1 (es) 2000-05-24
MA24484A1 (fr) 1998-10-01
PT968194E (pt) 2004-08-31
BR9807872A (pt) 2000-03-21
DZ2440A1 (fr) 2003-01-11
EP0968194B1 (en) 2004-05-26
WO1998038173A1 (en) 1998-09-03
ID22711A (id) 1999-12-09
KR100358636B1 (ko) 2002-10-31
PE58399A1 (es) 1999-06-16

Similar Documents

Publication Publication Date Title
YU41299A (sh) Atropizomeri 3-aril-4(3h)-hinazolinona i njihova upotreba kao ampa-receptor antagonista
BG107023A (en) 3-aminoquinazolin-2,4-dione antibacterial agents
DE60025189D1 (de) Cyanopyrrole als progesteronrezeptoragonisten
ATE405266T1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
TR200000333T2 (tr) Y alıcı antagonistleri olarak 4-aminopirol (3,2-d) pirimidinler.
DE60022042D1 (de) Thieno- und furopyrimidin derivate als a2a-rezeptor antagonisten
ATE302775T1 (de) Carbolinderivate
ATE250053T1 (de) Bradikinin b1 rezeptor antagonisten
DE69716925T2 (de) Isoxazoline derivate und ihre verwendung als antimikroben
HK1108882A1 (en) Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists
CO5150156A1 (es) IMIDAZO[4,5,1ij] QUINOLINONAS UTILES EN LA MANUFACTURA DE MEDICAMENTOS PARA EL TRATAMIENTO DE PERTURBACIONES SEXUALES .
MXPA03007142A (es) Derivados de carbolina.
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
MXPA02012076A (es) Compuestos quimicos.
DE60027700D1 (de) Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
MXPA02012659A (es) Derivados de pirazindiona condensados.
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
ATE296809T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ES2249309T3 (es) Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
PT1147087E (pt) Feantridina-n-oxidos com actividade de inibicao de pde-iv
MXPA05010651A (es) Compuestos de pirazol.
ATE281439T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
TW200505926A (en) 1,4-diazabicyclo [3.2.2] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
DE60122559D1 (de) Indolderivate als pde5-inhibitoren